The glycoconjugate pro-drug delivery platform consists of new compositions of matter re-engineered from existing pharmaceutical agents by proprietary chemical bonding to transport molecules. 


The chemical modification enables blood brain barrier transport of drugs that would not otherwise reach efficacious levels in the brain without the risk of systemic side-effects. 


The lead drug candidate in this platform is IPX-750 for the treatment of Parkinson’s disease.

Learn more:

Doctors discuss treatment of Parkinson's